Siamak Daneshmand, MD

The Oncology Brothers recap the discussion on treatment practices for patients with bladder cancer.

Focusing on the metastatic setting, the expert panel discusses advanced kidney cancer treatment practices, highlighting recent data that are informing treatment decisions.

Karine Tawagi, MD, and Sia Daneshmand, MD, offer comprehensive insights on treatment practices for patients with muscle-invasive bladder cancer.

Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer.

Although testicular cancer is a rare disease accounting for only 1% of all male neoplasms, it represents a paradigm for cancer curability. Overall, more than 95% of patients can expect to be cured of their disease with minimal long-term toxicity. Given these expectations, it is critical that cancer care providers are familiar with the diagnostic and therapeutic challenges encountered in these rare patients. In particular, clinicians managing these patients should be aware of some of the pitfalls encountered when determining relapse. In a series of case presentations, we review the evaluation and management of patients with persistent elevation of serum tumor markers and postchemotherapy residual radiographic abnormalities.